Goldman Sachs
JBIO

Goldman Sachs’s Jade Biosciences JBIO Stock Holding History

Goldman Sachs’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.15M Buy
153,037
+87,697
+134% +$1.27M ﹤0.01% 4471
2025
Q4 		$1.01M Sell
65,340
-97,371
-60% -$1.14M ﹤0.01% 5137
2025
Q3 		$1.4M Buy
+162,711
New +$1.33M ﹤0.01% 4787
2025
Q2 		– Sell
-10,076
Closed -$885K – 6078
2025
Q1 		$885K Buy
10,076
+1,094
+12% +$96.1K ﹤0.01% 4778
2024
Q4 		$833K Buy
8,982
+4,382
+95% +$378K ﹤0.01% 4942
2024
Q3 		$337K Buy
4,600
+2,001
+77% +$129K ﹤0.01% 5251
2024
Q2 		$151K Buy
+2,599
New +$1.72M ﹤0.01% 5332
2022
Q1 		– Sell
-536
Closed -$221K – 6560
2021
Q4 		$221K Buy
+536
New +$271K ﹤0.01% 5838
2021
Q3 		– Sell
-2,993
Closed -$2.39M – 6219
2021
Q2 		$2.39M Buy
+2,993
New +$2.39M ﹤0.01% 4032

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs's JBIO Position: Q1 2026 in Review

Goldman Sachs increased its Jade Biosciences (JBIO) stake by 134% in Q1 2026, buying an estimated $1.27M and bringing the position to 153,037 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #4471.

Goldman Sachs first reported a position in JBIO in Q2 2021 and has held it in 9 quarters since. The position peaked at $2.39M in Q2 2021. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • Goldman Sachs held 153,037 shares of Jade Biosciences worth $2.15M as of Q1 2026.
  • Goldman Sachs bought 87,697 Jade Biosciences shares in Q1 2026, an estimated $1.27M.
  • Jade Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4471 holding.
  • Goldman Sachs first reported a position in Jade Biosciences in Q2 2021 and has held it in 9 quarters since.
  • Goldman Sachs's Jade Biosciences position peaked at $2.39M in Q2 2021.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.